Moleculin Announces Acceptance of Abstract to be Presented at the American Association for Cancer Research (AACR) Annual Meeting 2023

Rhea-AI Summary

Moleculin Biotech, Inc. (Nasdaq: MBRX) announced that its abstract for the next-generation anthracycline, Annamycin, has been accepted for presentation at the AACR Annual Meeting 2023 from April 14-19, 2023 in Orlando, FL. The presentation, titled Exploration of Annamycin Organotropism, focuses on targeting liver cancers. Annamycin has shown potential in animal models for significantly improved localization over doxorubicin and reduced cardiotoxicity, enhancing its therapeutic prospects for treating acute myeloid leukemia and soft tissue sarcoma lung metastases.

Positive

• The abstract for Annamycin is accepted for presentation at a prestigious conference, enhancing visibility.
• Annamycin shows a 30-fold increase in accumulation in lungs compared to doxorubicin, indicating potential efficacy.
• The drug has demonstrated a lack of cardiotoxicity in early-stage human trials, which could broaden its application.

Negative

• None.

HOUSTON, March 21, 2023 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses, today announced that an abstract regarding the Company's next-generation anthracycline, Annamycin, has been selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2023, taking place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL.

Details of the presentation are as follows:

Title: Exploration of Annamycin Organotropism to Target Primary and Metastatic Liver Cancers 
Track: Experimental and Molecular Therapeutics
Session: PO.ET09.10 - Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases
Abstract Number: 4947 / 25
Presenter: Rafal Zielinski, Ph.D., Department of Experimental Therapeutics, Division of Cancer Medicine, MD Anderson Cancer Center
Date and Time: April 18, 2023, 1:30 p.m. - 5:00 p.m. ET
Location: Section 15

For more and to view the abstract, visit the AACR Annual Meeting website.

About Annamycin

Annamycin is the Company's next-generation anthracycline that has been shown in animal models to accumulate in the lungs at up to 30-fold the level of doxorubicin. Importantly, Annamycin has also demonstrated a lack of cardiotoxicity in multiple early-stage human clinical trials, including ongoing trials for the treatment of acute myeloid leukemia (AML) and STS lung metastases. For that reason, although additional data will be necessary, the Company believes Annamycin may not face the same usage limitations imposed on doxorubicin, one of the most common currently approved anthracyclines. Annamycin is currently in development for the treatment of AML and STS lung metastases and the Company believes the drug may have the potential to treat additional indications.

About Moleculin Biotech, Inc.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs, for hard-to-treat tumors and viruses. The Company's lead program, Annamycin is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity. Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Additionally, the Company is developing WP1066, an Immune/Transcription Modulator capable of inhibiting p-STAT3 and other oncogenic transcription factors while also stimulating a natural immune response, targeting brain tumors, pancreatic and other cancers, and WP1220, an analog to WP1066, for the topical treatment of cutaneous T-cell lymphoma. Moleculin is also engaged in the development of a portfolio of antimetabolites, including WP1122 for the potential treatment of COVID-19 and other viruses, as well as cancer indications including brain tumors, pancreatic and other cancers.

For more information about the Company, please visit www.moleculin.com and connect on Twitter, LinkedIn and Facebook.

Forward-Looking Statements

Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Although Moleculin believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. Moleculin has attempted to identify forward-looking statements by terminology including 'believes,' 'estimates,' 'anticipates,' 'expects,' 'plans,' 'projects,' 'intends,' 'potential,' 'may,' 'could,' 'might,' 'will,' 'should,' 'approximately' or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those discussed under Item 1A. "Risk Factors" in our most recently filed Form 10-K filed with the Securities and Exchange Commission ("SEC") and updated from time to time in our Form 10-Q filings and in our other public filings with the SEC. Any forward-looking statements contained in this release speak only as of its date. We undertake no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Investor Contact:

JTC Team, LLC
Jenene Thomas
(833) 475-8247 
MBRX@jtcir.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/moleculin-announces-acceptance-of-abstract-to-be-presented-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023-301776724.html

SOURCE Moleculin Biotech, Inc.

FAQ

What is the significance of the Annamycin abstract presentation at the AACR Annual Meeting 2023?

The acceptance of Moleculin's abstract for Annamycin at AACR 2023 highlights its potential and fosters interest in the drug's development.

When will the Annamycin presentation take place at the AACR Annual Meeting?

The Annamycin presentation is scheduled for April 18, 2023, from 1:30 p.m. to 5:00 p.m. ET.

What are the primary targets of Annamycin in clinical trials?

Annamycin is primarily aimed at treating acute myeloid leukemia (AML) and soft tissue sarcoma lung metastases.

How does Annamycin compare to traditional anthracyclines like doxorubicin?

Annamycin shows significantly greater localization in lung tissues and reduced cardiotoxicity, suggesting it may avoid the limitations faced by doxorubicin.